Compare HCA Health Inc (HCA) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Xpeng Inc - ADR — how do they compare? HCA Health Inc trades at $448.85 (market cap $96.35B), while Xpeng Inc - ADR trades at $9.88 (market cap $9.16B). The key difference: HCA Health Inc is far larger — about 10.5× Xpeng Inc - ADR's market cap, and HCA Health Inc pays a 0.7% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and Xpeng Inc - ADR for 80 Days on average.
| HCA | XPEV | |
|---|---|---|
Market Cap | $96.35B | $9.16B |
Volume | 1,079,453 | 5,030,325 |
Sector | Health | Consumer Cyclical |
52-Week High | $545.13 | $28.07 |
52-Week Low | $361.32 | $9.25 |
Typical Hold Time | 76 Days | 80 Days |
Enterprise Value | $146.88B | $11.09B |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $449.47, up 2.35% with bullish technical indicators and strong fundamental performance. The stock shows consistent earnings beats with Q2 2026 EPS of $7.59 exceeding expectations, while revenue growth continues from $75.6B in 2025 to projected $78.0B in 2026. Analyst consensus remains strongly positive with 63% buy ratings and $461.12 price target, though legal investigations present headwinds.
The outlook remains favorable with solid patient demand and operational efficiency driving growth, though investors should monitor ongoing legal investigations and debt levels. Valuation appears reasonable with P/E of 14.92 and EV/EBITDA of 9.26, while technical support at $440 provides near-term stability.
XPeng (XPEV) trades at $9.92, up 3.55% today, but remains in a bearish technical trend. The company shows mixed fundamentals with strong revenue growth to $76.72B in 2025 but persistent net losses. Recent Q2 2026 earnings missed expectations, though vehicle deliveries surged 65% quarter-over-quarter. Analyst consensus remains bullish with a $17.55 price target, representing 77% upside potential from current levels.
XPeng presents a high-risk, high-reward opportunity with significant growth potential in EVs and robotics, but profitability challenges and competitive pressures create substantial risk. The stock's current valuation at 0.81 P/S appears attractive if the company can achieve sustainable profitability, but investors face execution risk amid China's competitive EV market and global expansion challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
